TSHA insider filings

Taysha Gene Therapies, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen TSHA transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for TSHA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Taysha Gene Therapies, Inc.

FiledFormInsiderReported transactionsSource
2026-07-104Nagendran Sukumar — President and Head of R&D, DirectorSale (S): 200,000 @ $6.24EDGAR
2026-06-024Long Alison S — DirectorGrant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0EDGAR
2026-06-024Sepp-Lorenzino Laura — DirectorGrant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0EDGAR
2026-06-024Stalfort John A III — DirectorGrant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0EDGAR
2026-06-024Donenberg Phillip B. — DirectorGrant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0EDGAR
2026-04-134Nagendran Sukumar — President and Head of R&D, DirectorOption exercise (M): 19,021 @ $1.71 · Sale (S): 200,000 @ $4.46 · Option exercise (M): 19,021 (derivative) @ $0EDGAR
2026-02-064Alam Kamran — CHIEF FINANCIAL OFFICERSale (S): 1,655 @ $4.52EDGAR
2026-01-274Alam Kamran — CHIEF FINANCIAL OFFICERSale (S): 78,968 @ $4.75 · Sale (S): 23,849 @ $4.61EDGAR
2026-01-274Nagendran Sukumar — President and Head of R&D, DirectorSale (S): 89,132 @ $4.75 · Sale (S): 26,918 @ $4.61EDGAR
2026-01-274Nolan Sean P. — Chief Executive Officer, DirectorSale (S): 136,789 @ $4.75 · Sale (S): 41,312 @ $4.61EDGAR
2026-01-144Alam Kamran — CHIEF FINANCIAL OFFICERGrant/award (A): 359,000 @ $0 · Grant/award (A): 231,000 (derivative) @ $0EDGAR
2026-01-144Nagendran Sukumar — President and Head of R&D, DirectorOption exercise (M): 111,324 @ $0.70 · Option exercise (M): 88,676 @ $1.71 · Sale (S): 200,000 @ $4.71 · Grant/award (A): 427,000 @ $0 · Option exercise (M): 111,324 (derivative) @ $0 · Option exercise (M): 88,676 (derivative) @ $0 · +1 moreEDGAR
2026-01-144Nolan Sean P. — Chief Executive Officer, DirectorGrant/award (A): 1,008,000 @ $0 · Grant/award (A): 648,000 (derivative) @ $0EDGAR
2025-12-014Nagendran Sukumar — President and Head of R&D, DirectorOption exercise (M): 70,172 @ $0.70 · Option exercise (M): 39,953 @ $1.71 · Sale (S): 110,125 @ $4.75 · Option exercise (M): 260,047 @ $1.71 · Sale (S): 260,047 @ $4.51 · Option exercise (M): 70,172 (derivative) @ $0 · +2 moreEDGAR
2025-09-124Nagendran Sukumar — President and Head of R&D, DirectorOption exercise (M): 41,150 @ $0.70 · Sale (S): 200,000 @ $3.23 · Option exercise (M): 41,150 (derivative) @ $0EDGAR
2025-08-224Alam Kamran — CHIEF FINANCIAL OFFICERSale (S): 54,491 @ $2.85EDGAR
2025-08-224Nagendran Sukumar — President and Head of R&D, DirectorSale (S): 57,054 @ $2.85EDGAR
2025-06-044Long Alison S — DirectorGrant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0EDGAR
2025-06-044Sepp-Lorenzino Laura — DirectorGrant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0EDGAR
2025-06-044Stalfort John A III — DirectorGrant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0EDGAR
2025-06-044Donenberg Phillip B. — DirectorGrant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0EDGAR
2025-06-034Manning Paul B — 10% ownerPurchase (P): 750,000 @ $2.75EDGAR
2025-04-104/AAlam Kamran — CHIEF FINANCIAL OFFICERGrant/award (A): 12,462 (derivative) @ $0EDGAR
2025-03-134Alam Kamran — CHIEF FINANCIAL OFFICERTax withholding (F): 29,843 @ $1.69EDGAR
2025-01-034Alam Kamran — CHIEF FINANCIAL OFFICERGrant/award (A): 431,000 @ $0 · Grant/award (A): 431,000 (derivative) @ $0EDGAR
2025-01-034Nagendran Sukumar — President and Head of R&D, DirectorGrant/award (A): 324,500 @ $0 · Grant/award (A): 324,500 (derivative) @ $0EDGAR
2025-01-034Nolan Sean P. — Chief Executive Officer, DirectorGrant/award (A): 892,500 @ $0 · Grant/award (A): 892,500 (derivative) @ $0EDGAR
2024-07-014Manning Paul B — 10% ownerPurchase (P): 1,333,333 @ $2.25EDGAR
2024-05-314Long Alison S — DirectorGrant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0EDGAR
2024-05-314Sepp-Lorenzino Laura — DirectorGrant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0EDGAR
2024-05-314Stalfort John A III — DirectorGrant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0EDGAR
2024-05-314Donenberg Phillip B. — DirectorGrant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0EDGAR
2024-02-064Alam Kamran — CHIEF FINANCIAL OFFICERTax withholding (F): 1,288 @ $1.51EDGAR
2024-01-044Alam Kamran — Chief Financial OfficerGrant/award (A): 590,413 @ $0 · Grant/award (A): 590,413 (derivative) @ $0EDGAR
2024-01-044Nagendran Sukumar — President and Head of R&D, DirectorGrant/award (A): 863,617 @ $0 · Grant/award (A): 863,617 (derivative) @ $0EDGAR
2024-01-044Nolan Sean P. — Chief Executive Officer, DirectorGrant/award (A): 1,184,688 @ $0 · Grant/award (A): 1,184,688 (derivative) @ $0EDGAR
2023-12-184Alam Kamran — Chief Financial OfficerGrant/award (A): 187,582 (derivative) @ $0EDGAR
2023-12-184Nagendran Sukumar — President and Head of R&D, DirectorGrant/award (A): 334,005 (derivative) @ $0EDGAR
2023-12-184Nolan Sean P. — Chief Executive Officer, DirectorGrant/award (A): 466,550 (derivative) @ $0EDGAR
2023-11-204Manning Paul B — 10% ownerPurchase (P): 100,000 @ $1.63EDGAR
2023-11-034Long Alison S — DirectorGrant/award (A): 43,800 (derivative) @ $0EDGAR
2023-08-254Alam Kamran — Chief Financial OfficerSale (S): 33,000 @ $2.33EDGAR
2023-08-164Stalfort John A III — DirectorPurchase (P): 388,889 @ $0.90 · Purchase (P): 388,889 @ $0.90 · Gift (G): 50,000 @ $0EDGAR
2023-08-164Nolan Sean P. — Chief Executive Officer, DirectorPurchase (P): 444,444 @ $0.90EDGAR
2023-08-164Manning Paul B — 10% ownerPurchase (P): 16,466,667 @ $0.90EDGAR
2023-08-164Donenberg Phillip B. — DirectorPurchase (P): 111,111 @ $0.90EDGAR
2023-07-144Session R.A. II — 10% ownerSale (S): 80,528 @ $0.71 · Sale (S): 5,344 @ $0.70EDGAR
2023-06-264Stalfort John A III — DirectorGrant/award (A): 43,800 (derivative) @ $0EDGAR
2023-06-264Session R.A. II — 10% ownerSale (S): 10,508 @ $0.70 · Sale (S): 18,100 @ $0.70EDGAR
2023-06-264Donenberg Phillip B. — DirectorGrant/award (A): 36,200 (derivative) @ $0EDGAR

Recent 8-K events — Taysha Gene Therapies, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-258-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-228-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-028-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-198-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-048-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-10-168-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-10-098-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TSHA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs